Michael A. Thompson, MD, PhD is a hematologist/oncologist and medical director of the Early Phase Cancer Research Program at Aurora Health Care in Milwaukee, WI.
Dr. Thompson is a native of Minnesota. He received his Bachelor of Science degree in Molecular Biology from the University of Wisconsin - Madison, his Medical Degree from Mayo Medical School, Rochester, MN, and PhD in Molecular Pharmacology and Experimental Therapeutics from the Mayo Graduate School. He completed his Internal Medicine Residency at the Mayo Clinic College of Medicine. He obtained his Hematology/Oncology Fellowship at the University of Texas M. D. Anderson Cancer Center in Houston, TX. He is board certified in Internal Medicine, Medical Oncology, and Hematology. Dr. Thompson received the American Society of Clinical Oncology (ASCO) Young Investigator Aware in 2006 and the Achievement in Clinical Investigation Award through the M. D. Anderson Cancer Center Hematology-Oncology Fellowship Program in 2007. As a fellow he trained in the American Society of Hematology Clinical Research Training Institute (ASH CRTI).
He moved back to the Midwest, where he served as the Medical Director of Cancer Research at ProHealth Care Regional Cancer Center, as well as the local site Clinical Trials Lead Investigator of the NCI Community Cancer Centers Program (NCCCP) and national Co-Chair of the NCCCP Clinical Trials Portfolio/Accrual Log Working Group. He also was on the NCCCP Early Phase Working Group which focused on bringing new drugs to the community setting. In 2013 he joined Aurora Health Care as the Medical Director of the Early Cancer Research Program, Patient-Centered Research in the Aurora Research Institute.
Dr. Thompson has studied and published in the area of hematologic malignancies – myeloma, lymphoma, leukemia, and other cancers. He is on the Eastern Cooperative Oncology Group (ECOG) Myeloma Core Committee and the NCI Myeloma Steering Committee. He has a strong interest in clinical research in hematologic cancers as well as in new drug development in a variety of other tumor types.
He served on the ASCO Integrated Media/Technology/Education Committee and went through the ASCO Leadership Development Program. He is currently on the ASCO Cancer Research Committee and various research subcommittees. He is active in social media (Twitter: @mtmdphd) with national presentations on the topic of the use of social media in oncology. He has advised groups such as Doximity, HealthTap, Best Doctors, and pharmaceutical companies on the use of patient and physician social networks and established the first myeloma Twitter discussion forum #mmsm and helped set up the ECOG twitter feed @EAOnc #EAOnc He also blogs for the ASCO Connection.